Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025Business Wire • 12/01/25
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth BuildersThe Motley Fool • 11/30/25
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder CancerZacks Investment Research • 11/24/25
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic ApproachesBusiness Wire • 11/24/25
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder CancerBusiness Wire • 11/21/25
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/20/25
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend YieldSeeking Alpha • 11/20/25
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SCZacks Investment Research • 11/20/25
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?The Motley Fool • 11/20/25
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV TreatmentBenzinga • 11/19/25
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another StudyZacks Investment Research • 11/19/25